Lung Cancer in Immunosuppressed Patients

Presenter Information

Garrett Melby, Thomas Jefferson UniversityFollow
Andrew Bernstein, MD, Thomas Jefferson University HospitalFollow
Matthew Tucker, MD, Thomas Jefferson University HospitalFollow
Julia Palecki, MD, Thomas Jefferson University HospitalFollow
Zoe Begun, MD, Thomas Jefferson University Hospital
Amman Bhasin, MD, Thomas Jefferson University HospitalFollow
Tingting Zhang, PhD, Thomas Jefferson University
Ida Micaily, MD, Thomas Jefferson UniversityFollow

Start Date

5-3-2024 9:10 AM

End Date

5-3-2024 11:00 AM

Description

Background

- Lung cancer is the #1 cause of cancer-related mortality in U.S. adults

- Immune evasion is a key mechanism in tumor cell proliferation

• Immunosuppressed patients have higher lung cancer incidences and worse lung cancer outcomes

- Success of immunotherapies supports the role of host immune function in host tumor response

• Studies have shown immunotherapy to be safe and effective in a variety of immunosuppressed populations
• Immunosuppressed patients are often excluded from immunotherapy trials and under-treated with immunotherapy compared to immunocompetent cohorts

- This study aimed to assess the disease course, PD-L1 expression, and utilized treatment modalities across patients with different immunocompromising conditions with lung cancer

• Human Immunodeficiency Virus (HIV)
• Multiple Sclerosis (MS)
• Solid Organ Transplant Recipients

Keywords

lung cancer, immunocompromise, HIV, multiple sclerosis, solid organ transplant

Comments

Presented at the 2024 Jefferson Health Equity and Quality Improvement (HEQI) Summit.